Investigators presented initial results from the phase 3 RAMPART trial of adjuvant durvalumab monotherapy or combined with tremelimumab for resected primary renal cell carcinoma.

Researchers assessed the effectiveness of a modified SUNTRAC to identify risk of skin cancer in solid organ transplant recipients.

Increase seen in overall survival, especially among those with HER2+-positive cancers, with median increase of more than 10 months.

Oncology care gaps are more pronounced among rural populations, and in counties with higher levels of cancer mortality, health risks, and socioeconomic risks, researchers reported.

Exerkines, the molecular signals released through physical exertion, may be protective against radiation toxicities for patients with prostate cancer.

Given that only about 1 in 4 eligible individuals currently receive housing assistance, a potential benefit of extending housing assistance may be earlier-stage diagnoses of these cancers,” ...

Thrombosis occurs in more than 1 in 10 adults receiving PEGylated asparaginase (Asp)–based therapy for acute lymphoblastic leukemia (ALL), with a 4-fold ...

Disitamab vedotin plus toripalimab improved progression-free survival and overall survival when compared to chemotherapy.

Sevabertinib produced “robust and durable” responses in patients with HER2-mutant NSCLC, whether they were previously treated or untreated in the advanced setting, according to Xiuning Le, MD, PhD.

Consistently reaching guidelines at moderate levels over three decades associated with significant reduction in DSC risk.

CRT consisted of concomitant cisplatin (3 doses of 100 mg/m 2 every 3 weeks or 7 doses of 40 mg/m 2 every week) and radiotherapy (70 Gy in 35 fractions). A single dose of durvalumab (1500 mg) was ...

Researchers sought to determine whether survival outcomes for patients with early breast cancer was better with NACT or ACT when pCR was not achieved.